These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
110 related items for PubMed ID: 9260732
21. Phenytoin dosage adjustment in Saudi epileptics: utilization of steady-state pharmacokinetic parameters. Abduljabbar M, Al-Khamis K, Ogunniyi A, Daif AK, Al-Yamani M. Eur J Neurol; 1999 May; 6(3):331-4. PubMed ID: 10210914 [Abstract] [Full Text] [Related]
24. Preliminary study of the association between the elimination parameters of phenytoin and phenobarbital. Methaneethorn J, Panomvana D, Vachirayonstien T. Drug Metab Pers Ther; 2017 Sep 26; 32(3):151-156. PubMed ID: 28873066 [Abstract] [Full Text] [Related]
26. Non-steady state population kinetics of intravenous phenytoin. Frame B, Beal SL. Ther Drug Monit; 1998 Aug 26; 20(4):408-16. PubMed ID: 9712466 [Abstract] [Full Text] [Related]
27. Clinical relevance of genetic polymorphism in CYP2C9 gene to pharmacodynamics and pharmacokinetics of phenytoin in epileptic patients: validatory pharmacogenomic approach to pharmacovigilance. Kousar S, Wafai ZA, Wani MA, Jan TR, Andrabi KI. Int J Clin Pharmacol Ther; 2015 Jul 26; 53(7):504-16. PubMed ID: 25943175 [Abstract] [Full Text] [Related]
32. [Development of rapid genotyping methods for single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 2C19 (CYP2C19) and their clinical application in pediatric patients with epilepsy]. Yamamoto Y, Takahashi Y, Nishimura S, Ikumi Y, Mishima N, Kagawa Y. Yakugaku Zasshi; 2011 Jul 26; 131(5):809-15. PubMed ID: 21532277 [Abstract] [Full Text] [Related]
33. Population estimation regarding the effects of cytochrome P450 2C19 and 3A5 polymorphisms on zonisamide clearance. Okada Y, Seo T, Ishitsu T, Wanibuchi A, Hashimoto N, Higa Y, Nakagawa K. Ther Drug Monit; 2008 Aug 26; 30(4):540-3. PubMed ID: 18641551 [Abstract] [Full Text] [Related]
35. The effect of nefazodone on the single-dose pharmacokinetics of phenytoin in healthy male subjects. Marino MR, Langenbacher KM, Hammett JL, Nichola P, Uderman HD. J Clin Psychopharmacol; 1997 Feb 26; 17(1):27-33. PubMed ID: 9004054 [Abstract] [Full Text] [Related]
36. Lack of pharmacokinetic interaction between zileuton and phenytoin in humans. Samara E, Cavanaugh JH, Mukherjee D, Granneman GR. Clin Pharmacokinet; 1995 Feb 26; 29 Suppl 2():84-91. PubMed ID: 8620675 [Abstract] [Full Text] [Related]
37. Utilization of Km for phenytoin dosage after folate addition to patient regimen. Berg MJ, Ebert BE, Rivey MP, Schottelius DD. Ther Drug Monit; 1987 Sep 26; 9(3):304-5. PubMed ID: 3672574 [Abstract] [Full Text] [Related]
38. Serum albumin-adjusted phenytoin levels: an approach for predicting drug efficacy in patients with epilepsy, suitable for developing countries. Tandon M, Pandhi P, Garg SK, Prabhakar SK. Int J Clin Pharmacol Ther; 2004 Oct 26; 42(10):550-5. PubMed ID: 15516024 [Abstract] [Full Text] [Related]